WallStSmart
DWTX

Dogwood Therapeutics, Inc.

NASDAQ: DWTX · HEALTHCARE · BIOTECHNOLOGY

$1.86
-10.71% today

Updated 2026-06-05

Market cap
$50.44M
P/E ratio
1.28
P/S ratio
EPS (TTM)
$1.17
Dividend yield
52W range
$1 – $10
Volume
0.1M

Dogwood Therapeutics, Inc. (DWTX) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20182019202020212022202320242025
Total assets$65935.00$315900.00$31.47M$15.78M$8.37M$4.17M$94.31M$90.17M
Cash & equivalents$30026.00$309384.00$29.80M$14.01M$7.03M$3.32M$14.85M$6.52M
Current assets$42398.00$315900.00$31.47M$15.78M$8.37M$4.17M$16.54M$8.43M
Total liabilities$1.33M$5.26M$1.53M$1.28M$1.04M$358548.00$30.03M$15.27M
Current liabilities$1.33M$1.62M$1.53M$1.28M$1.04M$358548.00$3.18M$3.06M
Long-term debt$15.38M
Shareholder equity$-1.26M$-4.94M$29.94M$14.50M$7.33M$3.81M$64.28M$74.90M
Retained earnings$-15.15M$-17.62M$-27.97M$-43.93M$-56.17M$-61.47M$-73.82M$-108.08M
Accounts receivable$334.00$785.00$324.00
Inventory
Goodwill$0.00$11.81M$12.40M

Frequently asked questions

How much free cash flow does DWTX generate?

DWTX produced $-15.62M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is DWTX's balance sheet healthy?

DWTX holds $6.52M in cash and equivalents against — in long-term debt, on $74.90M of shareholder equity. That debt is best read against the cash flow the business throws off each year.